Lyra Therapeutics Files Q1 2025 10-Q
Ticker: LYRA · Form: 10-Q · Filed: May 6, 2025 · CIK: 1327273
| Field | Detail |
|---|---|
| Company | Lyra Therapeutics, INC. (LYRA) |
| Form Type | 10-Q |
| Filed Date | May 6, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, equity-offering, warrants
TL;DR
Lyra Therapeutics Q1 2025 10-Q is in. Equity offering details and costs disclosed.
AI Summary
Lyra Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The company reported on its financial position and operations, including details on common stock, warrants, and various cost categories like product development and facilities support. The filing also references a controlled equity offering sales agreement with Cantor Fitzgerald & Co. dated March 22, 2024.
Why It Matters
This filing provides investors with an update on Lyra Therapeutics' financial health and operational activities for the first quarter of 2025, including details on equity offerings and costs.
Risk Assessment
Risk Level: medium — The filing details financial activities including equity offerings and warrants, which can indicate financial strategy and potential dilution risks.
Key Numbers
- Q1 2025 — Reporting Period (Covers the first quarter of fiscal year 2025)
- 2025-03-31 — Period End Date (The end date for the financial reporting period)
- 2025-05-06 — Filing Date (The date the 10-Q was officially filed with the SEC)
Key Players & Entities
- Lyra Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- Cantor Fitzgerald & Co. (company) — Party to a controlled equity offering sales agreement
- March 22, 2024 (date) — Date of controlled equity offering sales agreement
FAQ
What is the primary purpose of this 10-Q filing for Lyra Therapeutics, Inc.?
This 10-Q filing provides a quarterly update on Lyra Therapeutics, Inc.'s financial position and operational results for the period ending March 31, 2025.
What specific financial instruments are mentioned in relation to Lyra Therapeutics' equity?
The filing mentions common stock, common warrants, and pre-funded warrants, as well as a controlled equity offering sales agreement with Cantor Fitzgerald & Co.
What is the date of the controlled equity offering sales agreement with Cantor Fitzgerald & Co.?
The controlled equity offering sales agreement with Cantor Fitzgerald & Co. is dated March 22, 2024.
What cost categories are specifically itemized in the filing?
The filing references product development and manufacturing costs, and facilities support costs and depreciation.
What is the former name of Lyra Therapeutics, Inc. mentioned in the filing?
The filing lists former names including 480 Biomedical, Inc., Arsenal Vascular, Inc., and Arsenal Medical, Inc.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 6, 2025 regarding Lyra Therapeutics, Inc. (LYRA).